In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 291 to 300 of 301

TitleTypeExpected publication date
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]Technology appraisal guidanceTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716Technology appraisal guidanceTBC
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672Technology appraisal guidanceTBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Technology appraisal guidanceTBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All